Education by a Nurse Increases Response of Patients With Chronic Hepatitis C to Therapy With Peginterferon-α2a and Ribavirin

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 9, 2011, Pages 781-785

  Larrey, Dominique ^a,b   Salse, Annie ^a   Ribard, Didier ^c   Boutet, Olivier ^d   Hyrailles Blanc, Valérie ^e   Niang, Birame ^f   Pageaux, Georges Philippe ^a   Vaucher, Emmanuel ^g   Arpurt, Jean Pierre ^h   Boulay, Guy ⁱ   Karlova, Natalia ^j   Daures, Jean Pierre ^k  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c DEPARTMENT OF NEUROLOGY   (France)

^d Hepato Gastroenterology   (France)

^e Centre Hospitalier Beziers   (France)

^f Ales Hospital   (France)

^g Narbonne Hospital   (France)

^h Avignon Hospital   (France)

ⁱ Hepato Gastroenterology   (France)

^j Laboratory Roche   (France)

^k UNIV MONTPELLIER   (France)

more..

Author keywords

Clinical Trial; HCV; Liver Disease; Prognosis; Virus

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSE CONSULTANT; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT REFERRAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIVIRAL AGENTS; EDUCATION, MEDICAL; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NURSES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 80052030968     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.05.022     Document Type: Article

References (16)

1. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
2. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
3. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
4. McHutchison J.G., Manns M., Patel K., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069. International Hepatitis Interventional Therapy Group.
5. Larrey D. Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?. Gastroenterol Clin Biol 2002, 26:B283-B290.
6. Russo M.W., Fried M.W. Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124:1711-1719.
7. Larrey D., Couzigou P., Denis J. Chronic hepatitis C: management of side effects of treatment. Gastroenterol Clin Biol 2007, 31:S20-S28.
8. Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005, 353:487-497.
9. Cramer J., Rosenheck R., Kirk G., et al. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003, 6:566-573.
10. TM: an experience in order to improve the global care of HIV infected patients. Med Mal Infect 2003, 33:117S-121S.
11. Pradier C., Bentz L., Spire B., et al. Efficacy of an educational and counselling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003, 4:121-131.
12. Leroy V., Hilleret M.N., Sturm N., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:775-782.
13. Cacoub P., Ouzan D., Melin P., et al. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008, 14:6195-6203.
14. Renou C., Lahmek P., Pariente A., et al. Impact of therapeutic education on the outcome of chronic hepatitis C treatment. Hepatology 2009, 50(Suppl 4):729A.
15. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
16. Bedossa P., Poynard T. An algorithm for the grading of activity in chronic hepatitis. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-293.